Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Gama Explorations, Inc. ( (TSE:SKNY) ) has provided an announcement.
LIR Life Sciences has entered Project Phase 2 of its peptide design program with Neuland Laboratories, advancing the development of next-generation cell-penetrating peptides that support its transdermal drug delivery platform for obesity treatments. Building on earlier synthesis work, this phase will use structure–activity relationship analysis to optimize synthetic variants of protamine-based peptide sequences, with the goal of identifying candidates that maintain strong transdermal transport while improving manufacturability and formulation flexibility; the results are expected to guide future synthesis, formulation, and biological testing, marking a key step in strengthening LIR’s technology foundation and positioning its platform for later-stage development.
More about Gama Explorations, Inc.
LIR Life Sciences Corp. is a biotechnology company focused on researching and developing scalable, affordable treatments for obesity using novel drug delivery methods. The company is advancing a transdermal patch and other delivery systems that mimic GLP-1, a hormone that regulates appetite and blood sugar, aiming to offer alternatives to injectable obesity drugs and to improve access, adherence, and cost-efficiency in both developed and emerging markets.
Average Trading Volume: 110,360
Technical Sentiment Signal: Buy
For detailed information about SKNY stock, go to TipRanks’ Stock Analysis page.